NNFN.SW Stock Analysis
NN
Uncovered
MannKind Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
MannKind Corp. operates as a biopharmaceutical company. The company is headquartered in Danbury, Connecticut and currently employs 391 full-time employees. The company went IPO on 2004-07-28. The firm is focused on the development and commercialization of therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The firm's technologies, Technosphere dry-powder formulations and Dreamboat inhalation devices offer convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The firm's products are Afrezza (insulin human) Inhalation Powder, and V-Go wearable insulin delivery device. Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. V-Go wearable insulin delivery device provides continuous subcutaneous infusion of insulin in adults that require insulin.